With its staggering incidence and prevalence world-wide, HF remains arguably the greatest unmet therapeutic need in cardiovascular medicine nowadays. Even with the advancements in SOC (standard of care) programs, mortality and morbidity is yet to be restrained. This then perpetuates the idea of an urgent call for advancement in the current pharmacological management entity. Besides, with the progress made on clarifying the pathogenesis of HF other than the notorious neuro-hormonal pathway, we now have plenty as plausible therapy targets. Which is why this thesis will focus on the advancements already made in pharmacological aspects of HF management and briefly discuss some of the plausible treatment entities.